Oral Manifestation in Patients With SARS-CoV2 Infection.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection .
Although many authors reported the presence of oral lesion associated with SARS-CoV2 infection, the prevalence of the oral manifestation and the range of oral manifestation are still unknown. Further studies are necessary to better understanding of the symptoms of the SARS-CoV2 virus in order to faster detection. A multidisciplinary team following the patients could be the key in treatment of the infection and faster recovery.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Fayoum, Egypt, 63514
- Faculty of dentistry
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- A diagnosis of SARS-CoV2 with PCR.
- Age range from 18-60 years old
Exclusion Criteria:
- Pregnancy or contraceptive pills
- Lactation
- Any auto-immune disease that could affect the oral mucosa
- On any neoplastic therapy.
- Uncontrolled diabetes
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
oral manifestation
Time Frame: one week
|
describe the patient oral manifestation
|
one week
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- La Rosa GRM, Libra M, De Pasquale R, Ferlito S, Pedulla E. Association of Viral Infections With Oral Cavity Lesions: Role of SARS-CoV-2 Infection. Front Med (Lausanne). 2021 Jan 14;7:571214. doi: 10.3389/fmed.2020.571214. eCollection 2020.
- Halboub E, Al-Maweri SA, Alanazi RH, Qaid NM, Abdulrab S. Orofacial manifestations of COVID-19: a brief review of the published literature. Braz Oral Res. 2020 Oct 30;34:e124. doi: 10.1590/1807-3107bor-2020.vol34.0124. eCollection 2020.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease Attributes
- Stomatognathic Diseases
- Mouth Diseases
- Severe Acute Respiratory Syndrome
- COVID-19
- Infections
- Communicable Diseases
- Oral Manifestations
Other Study ID Numbers
Other Study ID Numbers
- Oral SARS-CoV2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV Infection
-
NCT05638178CompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 Infection
-
NCT05973084RecruitingSARS CoV 2 Infection | SARS CoV 2 Vaccination
-
NCT06923137Active, not recruitingCOVID-19 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | COVID-19 Vaccines | SARS-CoV-2 Infection, COVID19 | COVID-19 Vaccination | SARS-CoV-2 Infection, COVID-19 | COVID-19 (Coronavirus Disease 2019) | COVID-19 SARS-CoV-2 Infection
-
NCT06806124CompletedSARS-CoV-2 Infection (Symptomatic) | COVID-19 Pulmonary Complications | SARS-CoV-2 Positive Patients | COVID19- Infection with SARS-CoV-2 Virus
-
NCT05358873CompletedSARS-CoV-2 Acute Respiratory Disease | SARS CoV 2 Infection
-
NCT05210101Completed
-
NCT05240378CompletedCancer | SARS CoV 2 Infection
-
NCT04583319Completed
-
NCT06097442RecruitingPost-acute Sequelae of SARS-COV-2 Infection
-
NCT04520880UnknownHospitalized Patients | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV 2 Infection) | Laboratory-confirmed SARS-CoV 2 Infection